JP5765634B2 - 低酸素活性化型プロドラッグを用いるがんの処置 - Google Patents

低酸素活性化型プロドラッグを用いるがんの処置 Download PDF

Info

Publication number
JP5765634B2
JP5765634B2 JP2011533309A JP2011533309A JP5765634B2 JP 5765634 B2 JP5765634 B2 JP 5765634B2 JP 2011533309 A JP2011533309 A JP 2011533309A JP 2011533309 A JP2011533309 A JP 2011533309A JP 5765634 B2 JP5765634 B2 JP 5765634B2
Authority
JP
Japan
Prior art keywords
cancer
administration
administered
combination
hap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011533309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506448A (ja
JP2012506448A5 (enExample
Inventor
ジェシカ サン，
ジェシカ サン，
ジョン ジー． クード，
ジョン ジー． クード，
ステュワート クロール，
ステュワート クロール，
マーク マッテウッチ，
マーク マッテウッチ，
チャールズ ピー． ハート，
チャールズ ピー． ハート，
チアン−シン デュアン，
チアン−シン デュアン，
Original Assignee
スレッシュホールド ファーマシューティカルズ， インコーポレイテッド
スレッシュホールド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッシュホールド ファーマシューティカルズ， インコーポレイテッド, スレッシュホールド ファーマシューティカルズ， インコーポレイテッド filed Critical スレッシュホールド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012506448A publication Critical patent/JP2012506448A/ja
Publication of JP2012506448A5 publication Critical patent/JP2012506448A5/ja
Application granted granted Critical
Publication of JP5765634B2 publication Critical patent/JP5765634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011533309A 2008-10-21 2009-10-21 低酸素活性化型プロドラッグを用いるがんの処置 Active JP5765634B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US10725308P 2008-10-21 2008-10-21
US61/107,253 2008-10-21
US11836808P 2008-11-26 2008-11-26
US61/118,368 2008-11-26
US15070009P 2009-02-06 2009-02-06
US61/150,700 2009-02-06
US15116309P 2009-02-09 2009-02-09
US61/151,163 2009-02-09
US24417209P 2009-09-21 2009-09-21
US61/244,172 2009-09-21
PCT/US2009/061541 WO2010048330A1 (en) 2008-10-21 2009-10-21 Treatment of cancer using hypoxia activated prodrugs

Publications (3)

Publication Number Publication Date
JP2012506448A JP2012506448A (ja) 2012-03-15
JP2012506448A5 JP2012506448A5 (enExample) 2012-12-13
JP5765634B2 true JP5765634B2 (ja) 2015-08-19

Family

ID=42119663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533309A Active JP5765634B2 (ja) 2008-10-21 2009-10-21 低酸素活性化型プロドラッグを用いるがんの処置

Country Status (5)

Country Link
US (2) US8946275B2 (enExample)
EP (1) EP2350664B1 (enExample)
JP (1) JP5765634B2 (enExample)
ES (1) ES2884674T3 (enExample)
WO (1) WO2010048330A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2389532T3 (es) 2005-06-29 2012-10-29 Threshold Pharmaceuticals, Inc. Profármacos alquilantes de fosforamidato
ES2649340T3 (es) 2010-07-12 2018-01-11 Threshold Pharmaceuticals, Inc. Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
MX2013011199A (es) 2011-04-01 2013-12-16 Threshold Pharmaceuticals Inc Metodos para tratar el cancer.
CA2832203A1 (en) * 2011-04-15 2012-10-18 Threshold Pharmaceuticals, Inc. Unit dose form for oral administration
WO2013096684A1 (en) * 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs and mtor inhibitors for treating cancer
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
ES2909741T3 (es) * 2012-02-21 2022-05-10 Immunogenesis Inc Tratamiento del cáncer
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014069063A1 (ja) 2012-10-29 2014-05-08 京セラ株式会社 弾性表面波センサ
EP2983591A4 (en) * 2013-04-10 2016-12-28 Threshold Pharmaceuticals Inc PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY
US20160158253A1 (en) 2013-07-26 2016-06-09 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US10131683B2 (en) 2014-07-17 2018-11-20 Molecular Templates, Inc. TH-302 solid forms and methods related thereto
MY192888A (en) 2015-03-10 2022-09-14 Ascentawits Pharmaceuticals Ltd Dna alkylating agents
EP3277381B1 (en) 2015-04-02 2026-01-07 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
AU2016282785A1 (en) 2015-06-24 2018-02-15 Immunogenesis, Inc. Aziridine containing DNA alkylating agents
CN108348463A (zh) * 2016-05-13 2018-07-31 泰克利森有限公司 用于治疗肝脏组织的方法
WO2018026606A1 (en) * 2016-08-01 2018-02-08 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
MX388198B (es) 2017-01-06 2025-03-19 Rivus Pharmaceuticals Inc Nuevos derivados de fenilo.
JP2019094284A (ja) * 2017-11-21 2019-06-20 日本化薬株式会社 ペメトレキセドを含有する注射用溶液製剤
CN109999183B (zh) * 2019-04-15 2021-03-09 中国科学技术大学 一种含有乏氧激活前药的纳米簇化酶及其制备方法和应用
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
EP4494643A4 (en) 2022-03-15 2025-09-10 Ascentawits Pharmaceuticals Ltd METHOD OF TREATING A PATIENT WITH BRCA MUTATION CANCER
WO2023198188A1 (zh) 2022-04-15 2023-10-19 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
WO2023226959A1 (zh) 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
EP4591866A1 (en) 2022-09-22 2025-07-30 Ascentawits Pharmaceuticals, Ltd. Use of hypoxia-activated compound in preparation of medicament for treating cancer patient
TW202434258A (zh) * 2023-02-27 2024-09-01 大陸商深圳艾欣達偉醫藥科技有限公司 溶液、凍乾製劑、凍乾製劑單位包裝、注射液及注射液配製方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636195A (en) 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
EP0383492A3 (en) 1989-02-14 1991-08-07 Thoro System Products Inc. Dispersion system for rapid curing cement compositions
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
JPH05507226A (ja) 1990-06-15 1993-10-21 コートラック・メディカル・インコーポレーテッド 薬物投与装置および方法
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
US6649193B1 (en) * 1999-06-11 2003-11-18 Henceforth Hibernia Inc. Prophylactic therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US7629332B2 (en) 2003-10-31 2009-12-08 Auckland Uniservices Limited Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
US20080132458A1 (en) 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
SE0400642D0 (sv) 2004-03-15 2004-03-15 Electrolux Ab Floor cleaning implement
US20090042820A1 (en) 2004-11-22 2009-02-12 Threshold Pharmaceuticals, Inc. Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
US20070117784A1 (en) 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
PT1871353E (pt) 2005-04-15 2011-03-29 Einstein Coll Med Vitamina k para prevenção e tratamento de irritação de pele secundária a terapia anti-egfr
ES2389532T3 (es) * 2005-06-29 2012-10-29 Threshold Pharmaceuticals, Inc. Profármacos alquilantes de fosforamidato
JP2009510165A (ja) * 2005-10-03 2009-03-12 ジェネティックス ファーマシューティカルズ， インク． 低酸素細胞を選択的に枯渇させるための方法
JP5596924B2 (ja) 2006-02-17 2014-09-24 カスケード プロドラッグ インコーポレイテッド ビンカアルカロイドｎ酸化物および類似体による過剰増殖疾患の処置
ES2884044T3 (es) 2006-12-26 2021-12-10 Immunogenesis Inc Profármaco alquilante de fosforamidato para el tratamiento del cáncer
WO2008151253A1 (en) 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
WO2009018163A1 (en) 2007-07-27 2009-02-05 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of anthracyclines
WO2009033165A1 (en) 2007-09-06 2009-03-12 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of bis-alkylating agents

Also Published As

Publication number Publication date
ES2884674T3 (es) 2021-12-10
EP2350664A1 (en) 2011-08-03
EP2350664A4 (en) 2014-04-30
EP2350664B1 (en) 2021-05-19
US20150258125A1 (en) 2015-09-17
WO2010048330A1 (en) 2010-04-29
US20130202716A1 (en) 2013-08-08
JP2012506448A (ja) 2012-03-15
US8946275B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
JP5765634B2 (ja) 低酸素活性化型プロドラッグを用いるがんの処置
EP2817011B1 (en) Treatment of cancer
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
TWI533866B (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途
JP2012506448A5 (enExample)
JP7193591B2 (ja) 化学療法の改善
CN102046187A (zh) 用于治疗癌症的方法和组合物
WO2010086964A1 (ja) がん治療のための併用療法
JP2021523169A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
TW201141473A (en) Combination therapy for small cell lung cancer
CN105283178A (zh) 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
US20170112807A1 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin c
CN103623394A (zh) 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
EP3463298B1 (en) Metronomic oral gemcitabine for cancer therapy
HK1204956B (en) Treatment of cancer
AU2004251444A1 (en) Cancer treatment with epothilones
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150601

R150 Certificate of patent or registration of utility model

Ref document number: 5765634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250